keyword
https://read.qxmd.com/read/38515317/the-relationship-between-hematologic-malignancies-on-male-hypogonadism-a-scoping-review
#1
JOURNAL ARTICLE
Bradley Roth, Muhammed A Moukhtar Hammad, Daniel I Sanford, Molly Piper, David W Barham, Faysal A Yafi, Lawrence C Jenkins
INTRODUCTION: The associated symptoms of hypogonadism have been reported in patients with various types of cancer. However, the prevalence and significance of hypogonadism among certain hematologic malignancies have not been completely summarized in recent literature. OBJECTIVE: In this review we aimed to examine the current literature on hypogonadism in patients with hematologic malignancies, with emphasis on leukemias, lymphomas, and multiple myeloma (MM). METHODS: This review included relevant studies published before July 2023 that were retrieved through a search of PubMed using the keywords "hematologic cancer," "hematologic malignancy," blood cancer," "leukemia," "lymphoma," "hypogonadism," "multiple myeloma," and "testosterone...
March 21, 2024: Sexual Medicine Reviews
https://read.qxmd.com/read/38511641/lsp1-promotes-the-progression-of-acute-myelogenous-leukemia-by-regulating-ksr-erk-signaling-pathway-and-cell-migration
#2
JOURNAL ARTICLE
Tan Li, Xiaochen Gui, Bin Li, Xueying Hu, Yuanyin Wang
We aimed to investigate the role and mechanism of LSP1 in the progression of acute myelogenous leukemia. In this study, we established shLSP1 cell line to analyze the function of LSP1 in AML. We observed high expression of LSP1 in AML patients, whereas it showed no expression in normal adults. Furthermore, we found that LSP1 expression was associated with disease prognosis. Our results indicate that LSP1 plays a crucial role in mediating proliferation and survival of leukemia cells through the KSR/ERK signaling pathway...
December 2024: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/38496190/atypical-peripheral-retinal-necrosis-without-ocular-inflammation-and-retinal-whitening-in-a-patient-with-acute-myelogenous-leukemia-a-case-report
#3
Yoshihiro Nakagawa, Xue Tan, Hikari Yoshida, Takahiro Suzuki, Yasuyuki Suzuki
Retinal necrosis is a severe condition that threatens visual function. It is caused by viruses that are known to cause acute retinal necrosis (ARN) and progressive outer retinal necrosis (PORN), which are called necrotizing herpetic retinopathies (NHR). ARN causes severe intraocular inflammation, including anterior chamber intravitreal cells, keratic precipitate, vitreous opacity, and retinal vasculitis, whereas intraocular inflammation in PORN is considered mild or virtually absent. In addition, PORN is a disease that manifests in immunosuppressive patients, such as those with acquired immunodeficiency syndrome...
February 2024: Curēus
https://read.qxmd.com/read/38487334/periorbital-necrotizing-sweet-syndrome-a-report-of-two-cases-mimicking-necrotizing-soft-tissue-infections
#4
Hursuong Vongsachang, Carolina A Chiou, Amee D Azad, Lisa Y Lin, Michael K Yoon, Daniel R Lefebvre, Anna M Stagner
PURPOSE: Two cases are described of necrotizing Sweet syndrome (nSS), a rare variant of acute febrile neutrophilic dermatosis that mimics necrotizing soft tissue infections. OBSERVATION: A 74-year-old female with myelodysplastic syndrome (MDS) presented with isolated periorbital nSS that closely mimicked necrotizing fasciitis (NF); she displayed pathergy to debridement, was exquisitely responsive to corticosteroids, and underwent successful first-stage reconstruction of the eyelid with full-thickness skin grafting...
June 2024: American Journal of Ophthalmology Case Reports
https://read.qxmd.com/read/38451195/therapeutic-targeting-of-tim-4-l-with-engineered-t-cells-for-acute-myeloid-leukemia
#5
JOURNAL ARTICLE
Brandon Cieniewicz, Edson Oliveira, Mike Saxton, Damoun Torabi, Ankit Bhatta, Phanidhar Kukutla, Alexander Arballo, Zhuo Yang, Bi Yu, Maria Fate, Hongxiu Ning, Lawrence Corey, Abhishek Maiti, Daniel Corey
PURPOSE: Disruption of lipid bilayer asymmetry is a common feature observed in cancer cells and offers novel routes for therapeutic targeting. We utilized the natural immune receptor TIM-4 to interrogate for loss of plasma membrane phospholipid polarity in primary acute myelogenous leukemia (AML) samples and evaluated the anti-leukemic activity of TIM-4-L-directed T cell therapy in preclinical AML models. METHODS: We performed FACs analysis on 33 primary AML bone marrow specimens and correlated TIM-4-L expression frequency and intensity with molecular disease characteristics...
March 7, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38421713/nkt-licensed-in-vivo-dendritic-cell-based-immunotherapy-as-cellular-immunodrugs-for-cancer-treatment
#6
JOURNAL ARTICLE
Shin-Ichiro Fujii, Kanako Shimizu
With the advent of new therapies, immunotherapy has gained attention as a critical modality. After the discovery of the natural killer T (NKT) cells ligand, ex vivo cultured dendritic cells (DCs) loaded with NKT ligand (especially α-galactosylceramide (α-GalCer) (DC/Gal) or ex vivo expanded NKT transfer studies were clinically examined in several institutes. To prevent tumoral immune escape, the link between innate and adaptive immunity, in situ selective targeting of DCs has been attempted; however, protocol optimization was required...
2024: Critical Reviews in Oncogenesis
https://read.qxmd.com/read/38405900/coordinated-immune-cell-networks-in-the-bone-marrow-microenvironment-define-the-graft-versus-leukemia-response-with-adoptive-cellular-therapy
#7
Katie Maurer, Cameron Y Park, Shouvik Mani, Mehdi Borji, Livius Penter, Yinuo Jin, Jia Yi Zhang, Crystal Shin, James R Brenner, Jackson Southard, Sachi Krishna, Wesley Lu, Haoxiang Lyu, Domenic Abbondanza, Chanell Mangum, Lars Rønn Olsen, Donna S Neuberg, Pavan Bachireddy, Samouil L Farhi, Shuqiang Li, Kenneth J Livak, Jerome Ritz, Robert J Soiffer, Catherine J Wu, Elham Azizi
Understanding how intra-tumoral immune populations coordinate to generate anti-tumor responses following therapy can guide precise treatment prioritization. We performed systematic dissection of an established adoptive cellular therapy, donor lymphocyte infusion (DLI), by analyzing 348,905 single-cell transcriptomes from 74 longitudinal bone-marrow samples of 25 patients with relapsed myeloid leukemia; a subset was evaluated by protein-based spatial analysis. In acute myelogenous leukemia (AML) responders, diverse immune cell types within the bone-marrow microenvironment (BME) were predicted to interact with a clonally expanded population of ZNF683 + GZMB + CD8+ cytotoxic T lymphocytes (CTLs) which demonstrated in vitro specificity for autologous leukemia...
February 12, 2024: bioRxiv
https://read.qxmd.com/read/38371630/parp-inhibitor-maintenance-treatment-for-newly-diagnosed-ovarian-cancer-patients-a-real-world-study-from-china
#8
JOURNAL ARTICLE
Jinghong Chen, Mengpei Zhang, Kemin Li, Yuanqiong Duan, Jing Zeng, Qingli Li, Danqing Wang, Liang Song, Qintong Li, Rutie Yin
PURPOSE: This study evaluated the efficacy and safety in a real-world population of epithelial ovarian cancer (EOC) treated with poly (ADP-ribose) polymerase inhibitor (PARPi) as first-line maintenance therapy in the largest gynecologic oncology center in Western China. METHODS: This study included patients newly diagnosed EOC who received PARPi as first-line maintenance therapy in West China Second University Hospital from August 1, 2018 to September 31, 2022. The primary endpoints were progression-free survival (PFS) and safety evaluated by Common Terminology Criteria for Adverse Events Version 5...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38339429/new-approaches-for-the-treatment-of-aml-beyond-the-7-3-regimen-current-concepts-and-new-approaches
#9
REVIEW
Jaime L Roman Diaz, Mariola Vazquez Martinez, Farhad Khimani
Fifty years have passed since the development of the first chemotherapy regimen for treating acute myelogenous leukemia (AML), with the approval in 1973 of the cytarabine daunorubicin (7+3) regimen. Until recently, patients diagnosed with AML had very limited treatment options and depended primarily on chemotherapy in combinations, doses, or schedules of the same drugs. Patients with advanced age, comorbidities, or relapsed or refractory disease were left with no effective options for treatment. New advances in the understanding of the biology and the molecular and genetic changes associated with leukemogenesis, as well as recent advances in drug development, have resulted in the introduction over the last few years of novel therapeutic agents and approaches to the treatment of AML as well as a new classification of the disease...
February 5, 2024: Cancers
https://read.qxmd.com/read/38331415/the-siren-song-of-synergy
#10
JOURNAL ARTICLE
Patrick D Bhola, Anthony Letai
In ancient Greek mythology, sirens were creatures of stunning beauty whose mystical songs led sailors to sail their boats onto hidden rocks and into total destruction. In this issue, Mason-Osann and colleagues present data in the context of acute myelogenous leukemia to suggest that while synergy may show initial attractions in drug combinations, it may carry with it hazards previously unforeseen. See related article by Mason-Osann et al. (1).
February 8, 2024: Blood cancer discovery
https://read.qxmd.com/read/38313606/an-uncommon-case-of-upper-extremity-mucormycosis-in-a-patient-with-acute-myeloid-leukemia
#11
Teren Yedikian, Ryu Yoshida, Meghan McCullough, Peter Deptula, David Kulber
Upper-extremity mucormycosis is a rare, life-threatening fungal infection mainly affecting immunocompromised patients. We report a case of a 30-year-old woman with acute myelogenous leukemia who developed this infection during her hospital stay. The culprit was Mucorales, a subgroup of Zygomycetes species known for fast-progressing, highly lethal infections. She presented with fever, chills, and a lesion on her left forearm that worsened despite initial broad-spectrum antibiotics. A punch biopsy confirmed the diagnosis, leading to antifungal therapy with isavuconazonium sulfate and later amphotericin B, combined with surgery...
January 2024: Journal of hand surgery global online
https://read.qxmd.com/read/38299340/statement-of-retraction-mycn-contributes-to-the-sensitization-of-acute-myelogenous-leukemia-cells-to-cisplatin-by-targeting-sry-box-transcription-factor-4
#12
(no author information available yet)
No abstract text is available yet for this article.
December 2024: Bioengineered
https://read.qxmd.com/read/38294290/identification-and-validation-of-stat4-as-a-prognostic-biomarker-in-acute-myeloid-leukemia
#13
JOURNAL ARTICLE
Chenyu Li, Jingyuan Zhao, Bingyu Kang, Shuai Li, Jingya Tang, Deshi Dong, Yanwei Chen
Acute myelogenous leukemia (AML) is a common malignancy and is supposed to have the ability to escape host immune surveillance. This study aimed to identify key genes in AML that may affect tumor immunity and to provide prognosis biomarkers of AML. The Cancer Genome Atlas (TCGA) dataset was screened for transcription factors (TFs) involved in immunity and influencing survival, combining Gene Expression Omnibus (GEO) data to validate the impact on patient survival. A prognostic signature was established using four transcription factors, and these genes play an important role in the immune system, with higher regulatory T cell (Treg) scores in high-risk patients compared to the low-risk group...
January 31, 2024: Bioscience Reports
https://read.qxmd.com/read/38224637/discovery-of-novel-selective-phosphodiesterase%C3%A2-1-inhibitors-for-the-treatment-of-acute-myelogenous-leukemia
#14
JOURNAL ARTICLE
Mei-Ling Le, Yi-Yi Yang, Mei-Yan Jiang, Chuan Han, Zhi-Rong Guo, Run-Duo Liu, Zheng-Jiong Zhao, Qian Zhou, Shijun Wen, Yinuo Wu
Acute myelogenous leukemia (AML) is the most common form of acute leukemia in adults. PDE1 (Phosphodiesterase 1) is a subfamily of the PDE super-enzyme families that can hydrolyze the second messengers cAMP and cGMP simultaneously. Previous research has shown that suppressing the gene expression of PDE1 can trigger apoptosis of human leukemia cells. However, no selective PDE1 inhibitors have been used to explore whether PDE1 is a potential target for treating AML. Based on our previously reported PDE9/PDE1 dual inhibitor 11a, a series of novel pyrazolopyrimidinone derivatives were designed in this study...
January 10, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38216005/properties-of-fda-approved-small-molecule-protein-kinase-inhibitors-a-2024-update
#15
REVIEW
Robert Roskoski
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 80 FDA-approved therapeutic agents that target about two dozen different protein kinases and seven of these drugs were approved in 2023. Of the approved drugs, thirteen target protein-serine/threonine protein kinases, four are directed against dual specificity protein kinases (MEK1/2), twenty block nonreceptor protein-tyrosine kinases, and 43 inhibit receptor protein-tyrosine kinases...
February 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38181249/a-case-report-of-acute-promyelocytic-leukemia-with-mycosis-fungoides
#16
JOURNAL ARTICLE
Shasha Dong, Yejing Zhu, Fang Zhang, Yongqin Zhao, Hongjing Zhou
RATIONALE: Acute promyelocytic leukaemia (APL) is a rare subtype of acute myelogenous leukaemia. With advances in treatment regimens, namely, introduction of all-trans-retinoicacid, outcomes have drastically improved, its side effects should not be ignored. Mycosis fungoides is one of the side effects of all-trans-retinoicacid treatment, but it may also be a clinical manifestation before disease progression. However, it rarely appears and is easily overlooked. This leads to being easily misled during the treatment process, affecting the treatment plan, and resulting in adverse consequences...
January 5, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38164785/treatment-of-relapsed-or-refractory-flt-3-acute-myelogenous-leukemia-with-a-triplet-regimen-of-hypomethylating-agent-venetoclax-and-gilteritinib
#17
JOURNAL ARTICLE
Dat Ngo, Jose Tinajero, Shanpeng Li, Joycelynne Palmer, Hoda Pourhassan, Ahmed Aribi, Ryotaro Nakamura, Anthony Stein, Guido Marcucci, Amandeep Salhotra, Karamjeet Sandhu, Vinod Pullarkat, Brian Ball, Paul Koller
Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies are limited in combining gilteritinib with a hypomethylating agent and venetoclax treatment backbone (HMA-VEN-GILT). Here we report our experience with HMA-VEN-GILT for 22 R/R FLT3 AML patients. HMA-VEN-GILT yielded an ORR of 77.3% (17/22), CR 4.5% (1/22), CRi 13...
March 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38154071/infectious-complications-of-venetoclax-treatment-of-hematologic-malignancies-a-systematic-review-and-meta-analysis
#18
JOURNAL ARTICLE
Connor Prosty, Khaled Katergi, Alex Nguyen, Owen Dan Luo, Mark Sorin, Vladimir Cherniak, Michael Sebag, Koray Demir, Emily G McDonald, Todd C Lee, Matthew P Cheng
Venetoclax is a small molecule inhibitor of BCL-2 used in the treatment of acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL). Recent post-marketing studies of ibrutinib, another small molecule inhibitor, suggested that these agents may predispose to opportunistic infections (OIs). We sought to systematically review the randomized controlled trial (RCT) evidence for venetoclax to assess whether it predisposes patients to infectious adverse events (IAEs) and neutropenia. We systematically reviewed RCTs comparing venetoclax therapy to active or placebo controls in patients with hematologic malignancies...
December 28, 2023: Blood Advances
https://read.qxmd.com/read/38149021/report-on-hematopoietic-cell-transplantations-performed-in-2018-2019-focusing-on-the-trends-of-selection-of-stem-cell-sources-in-the-asia-pacific-region-apbmt-activity-survey
#19
JOURNAL ARTICLE
Minako Iida, Kaiyan Liu, Xiao Jun Huang, He Huang, Yachiyo Kuwatsuka, Joon Ho Moon, Jong Wook Lee, Kavitha M Lakshmi, Anthony Dodds, Leonie Wilcox, Bor-Sheng Ko, Amir Ali Hamidieh, Maryam Behfar, Kim Wah Ho, Udomsak Bunworasate, Aloysius Ho, Tasneem Farzana, Joycelyn Sim, Phu Chi Dung, Mafruha Akter, Wasantha Ratnayake, Marjorie Rose Bravo, Aye Aye Gyi, Damai Santosa, Bishesh Sharma Poudyal, Khishigjargal Batshkh, Alok Srivastava, Shinichiro Okamoto, Yoshiko Atsuta
The number of hematopoietic stem cell transplantations (HCTs) is increasing annually worldwide, and the Asia-Pacific (AP) region is no exception. We report on the absolute number of HCTs in 2018 and 2019 and the trends in graft selection and disease indication in the past few decades. In 2018, 24,292 HCTs were performed in the AP region, of which 8,754 (36.0%) were autologous and 15,538 (64.0%) were allogeneic. Among the allogeneic HCTs, 10,552 (67.9%) of the recipients were related to their donors, whereas 4,986 (32...
November 25, 2023: Blood Cell Ther
https://read.qxmd.com/read/38139160/unsymmetrical-pd-ii-pincer-complexes-with-benzothiazole-and-thiocarbamate-flanking-units-expedient-solvent-free-synthesis-and-anticancer-potential
#20
JOURNAL ARTICLE
Vladimir A Kozlov, Diana V Aleksanyan, Svetlana G Churusova, Aleksandr A Spiridonov, Ekaterina Yu Rybalkina, Evgenii I Gutsul, Svetlana A Aksenova, Alexander A Korlyukov, Alexander S Peregudov, Zinaida S Klemenkova
Driven by the growing threat of cancer, many research efforts are directed at developing new chemotherapeutic agents, where the central role is played by transition metal complexes. The proper ligand design serves as a key factor to unlock the anticancer potential of a particular metal center. Following a recent trend, we have prepared unsymmetrical pincer ligands that combine benzothiazole and thiocarbamate donor groups. These compounds are shown to readily undergo direct cyclopalladation, affording the target S , C , N -type Pd(II) pincer complexes both in solution and in the absence of a solvent...
December 10, 2023: International Journal of Molecular Sciences
keyword
keyword
161148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.